NR4A1 and breast carcinoma: In this study, a total of 60 patients in the breast cancer group were divided into three groups according to the molecular typing method, including 25 patients in the hormone receptor-positive group, 25 patients in the HER-2-positive group, and 10 patients in the triple-negative group, in combination with intraoperative or postoperative immunohistochemistry of the patients.